Plain-English translation of NCT01913106 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostatic Neoplasms research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach called HSV-tk gene therapy combined with standard brachytherapy (radioactive seed placement) for men whose prostate cancer has returned after previous radiation treatment. The gene therapy works by introducing a special gene into cancer cells that makes them sensitive to an antiviral medication, allowing the cancer cells to die while sparing healthy tissue. This treatment is designed for patients who have limited other options.
Men whose prostate cancer comes back after radiation therapy have very few effective treatment choices. This trial exists to see if combining the gene therapy with radioactive seeds can offer these patients a better way to control their cancer with acceptable safety.
You likely qualify if…
You likely don't qualify if…
You would start taking an antibiotic pill twice daily for 3–5 days and an antiviral medication (Valtrex) three times daily for 14 days, beginning the day before your procedure. On the day after starting these medications, you would undergo brachytherapy (placement of radioactive seeds into your prostate), and immediately afterward, while still in the operating room, you would receive an injection of the gene therapy directly into your prostate. You would keep a pill diary to track your medication doses and return for follow-up visits to monitor your response.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States